Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 17/20 | 0.74 |
| ▸ | BCL2 | P10415 | 14/20 | 0.74 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15948813 | 0.91 | BCL2L1 (0.61) | BCL2L1BCL2BCL2L2 | |
| SCHEMBL15948814 | 0.91 | BCL2L1 (0.61) | BCL2L1BCL2BCL2L2 | |
| SCHEMBL9951285 | 0.90 | BCL2 (0.81) | BCL2L1BCL2BCL2L2 | |
| SCHEMBL9951277 | 0.90 | BCL2 (0.81) | BCL2L1BCL2BCL2L2 | |
| SCHEMBL9951797 | 0.88 | BCL2 (0.83) | BCL2L1BCL2BCL2L2 | |
| SCHEMBL9951792 | 0.88 | BCL2 (0.83) | BCL2L1BCL2BCL2L2 | |
| SCHEMBL10206285 | 0.86 | BCL2L1 (0.80) | BCL2L1BCL2BCL2L2 | |
| SCHEMBL9951373 | 0.86 | BCL2 (0.88) | BCL2L1BCL2BCL2L2 | |
| SCHEMBL9951368 | 0.86 | BCL2 (0.88) | BCL2L1BCL2BCL2L2 | |
| SCHEMBL9950442 | 0.85 | BCL2 (0.91) | BCL2L1BCL2BCL2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809352-B2 | Sulfonamides as inhibitors of Bcl-2 family proteins for the treatments of cancer | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| US-8809352-B2 | Sulfonamides as inhibitors of Bcl-2 family proteins for the treatments of cancer | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| EP-2475661-B1 | SULFONAMIDES AS INHIBITORS OF BCL-2 FAMILY PROTEINS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | BCLAF1, BCL2L11, BCL2 | BCL2L1 4/4885BCL2 3/4885BCL2L2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.